NCT07218315View on ClinicalTrials.gov

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2031

Conditions
Thyroid Carcinoma
Interventions
DEVICE

CellFX nsPFA Percutaneous Electrode System

Patients will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT07218315 - Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma | Biotech Hunter | Biotech Hunter